# Integration Result — INTEGRATION-E001-01

**Instruction:** MADARAII-34  
**Commission:** human Commission act authorizing integration of useful first-Jester results  
**Pre-Product:** `PRODUCT-0001 / b2cafabba970245b7ccb24f6f01a3ca2e2ba9681`  
**Verified candidate:** `4a7c1d5b2bea939ebd508dcce19c4e93f58149cf`  
**Verification:** `VERIFICATION-E001-01`  
**Resulting Product:** `PRODUCT-0001 / 4a7c1d5b2bea939ebd508dcce19c4e93f58149cf`  
**Resulting Target HOW:** `TARGET-HOW-0001` revision 4

## Admission precheck

Immediately before integration, Product owner still resolved predecessor `b2caf...`. Compare from verified candidate `4a7c...` to repository `main` showed only epoch Work/Result files had changed since candidate creation; no Product owner surface had drifted. The integrated Product configuration is therefore byte/configuration-identical at the declared Product surfaces to the configuration verified by `VERIFICATION-E001-01`.

No post-integration MADARAII-33 rerun was required because admission performed no Product transformation beyond owner-state transition. Knowledge/Evidence/Work Plane write-back is outside the Product surface set.

## Fan-in semantics

There is one dependent repair candidate, not competing alternatives. Its four repair slices are a coherent composition from `PLAN-E001-01`; none is selected independently or superseded by arrival order. The predecessor Product remains historical and reproducible but is superseded as current state.

## Owner transition and accepted changes

Product owner transitioned:

`b2cafabba970245b7ccb24f6f01a3ca2e2ba9681 → 4a7c1d5b2bea939ebd508dcce19c4e93f58149cf`.

The admitted revision preserves the same MiniDoc 0.1 feature boundary while accepting these mechanism corrections:

- candidate-first replacement-document/session admission;
- monotonic freshness fencing for asynchronous PDF presentation;
- coherent `Table.Columns` metadata under simple-table add/delete column operations;
- explicit `target integrity unknown` semantics when both direct write and recovery fail.

`TARGET-HOW-0001` revision 4 now owns these mechanisms. `EV-E001-01` owns the post-repair Windows CI evidence route. Target WHAT revision 2 remains current and unchanged.

## Verification and supported reliance

Windows CI run `34972485636` succeeded on exact candidate `4a7c...`: build/semantic checks/package, Product dependency boundary, install/PDF normal-close process exit/uninstall residue, and artifact upload all passed. Artifact `10397718020` has digest `sha256:8f75b3584f93ee8ddf9073a6371f6d365fb1fba23b7c6fa5c678817a5788fbb4`.

Source/state-machine evidence supports the session-replacement, PDF freshness, and dual-failure semantics within the limitations stated by `VERIFICATION-E001-01`. Admission does not enlarge those evidence claims.

## Actual effects and non-effects

Authoritative Product and affected Target HOW/Evidence owners changed. No release, deployment, local installation, registry mutation, external-system call, user-document mutation, migration, or operating-environment activation occurred through integration.

The prior Product `b2caf...` is `SUPERSEDED_AS_CURRENT / RETAINED_HISTORICALLY`. Candidate `4a7c...` is `ADMITTED_CURRENT`, no longer candidate-only.

## Downstream impact

- second Jester becomes eligible against the exact admitted Product Baseline `4a7c...` and Target HOW revision 4;
- first-Jester repair Plan/Implementation/Verification contour is terminal except for historical/reporting use;
- no Target WHAT, Product Architecture, installer, Roadmap, release, or deployment reopening is required;
- pre-existing Windows 11 interactive/visual and broad document-population evidence limits remain bounded gaps, not blockers to the commissioned second Jester/finalization contour.

## Recovery / reopen

The predecessor Product remains reproducible from `b2caf...`. Reopen affected repair/integration scope only on contradictory evidence, Product-surface drift, or a later reproducer of one of the admitted repair failure classes.

**Status:** integration complete; exact new Product Baseline authoritative and reproducible.
